Category

Archives

ALK

Case Report of CCDC149-ALK fusion: a novel genetic alteration and a clinically relevant target in metastatic papillary thyroid carcinoma

0 views | Sep 26 2022

Hannah Lee et al. recommend deep mutational sequencing in BRAFV600E-negative, RAIR PTC to identify targetable genetic alterations, including gene fusions, that might result in dramatic therapeutic benefits. [Read the Full Post]

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

38 views | Aug 01 2022

Navneet Singh et al. thought that for patients with an anaplastic lymphoma kinase rearrangement, a performance status (PS) of 0-2, and previously untreated NSCLC, clinicians should offer alectinib or brigatinib or lorlatinib. [Read the Full Post]

Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature

54 views | Jul 18 2022

Xi Lei et al. recommend alectinib for the first-line treatment of metastatic PC with EML4-ALK fusion. [Read the Full Post]

Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis

95 views | Jun 05 2022

Kehai Lin et al. thought that lorlatinib in never-smokers and low-dose alectinib in smokers could be considered optimal first-line therapy for advanced ALK-positive NSCLC. [Read the Full Post]

A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines

92 views | Jun 03 2022

Yutao Li et al. supported the idea that combination therapies offer significant potential when they are optimized on a patient-by-patient basis. [Read the Full Post]

Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion

112 views | Jun 02 2022

Xuehua Xie et al. described a case of MPM with CD74-ROS1 fusion who obtained complete and durable response after receiving crizotinib. [Read the Full Post]

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study

119 views | May 09 2022

Kadir Eser et al. found that concomitant usage of PPIs was associated with shorter PFS in mBC treated with both ribociclib and especially palbociclib. [Read the Full Post]

Iguratimod Inhibits Skin Fibrosis by regulating TGF-β1/Smad Signaling Pathway in Systemic Sclerosis

175 views | Apr 22 2022

Xi Xie et al. indicated T614 inhibited dermal fibroblasts activation and skin fibrosis at least partly by regulating TGF-β1/smad pathway in experimental SSc models and might be a promising therapeutic agent for SSc. [Read the Full Post]

Insulin-like signaling promotes limb regeneration in the Chinese mitten crab (Eriocheir sinensis)

179 views | Mar 20 2022

Ju Li et al. identified a conserved insulin-like receptor in E. sinensis, and provided new evidence for the involvement of ILS in the regulation of limb autotomy and regeneration in crustaceans. [Read the Full Post]

Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis

420 views | Dec 11 2021

Vikrant Palande et al. found that new avenues for precision medicine in GBM, using non-invasive liquid biopsy diagnostics to assess personalized patient profiles. Moreover, repeated detection of druggable targets over the course of the disease may provide real-time information on the evolving molecular landscape of the tumour. [Read the Full Post]